Increased Serum Trimethylamine N-Oxide Level in Type 2 Diabetic Patients with Mild Cognitive Impairment
Nongzhang Xu,Jianwei Wan,Cuihong Wang,Jiatao Liu,Chenqai Qian,Hongyang Tan
DOI: https://doi.org/10.2147/DMSO.S370206
2022-07-27
Abstract:Nongzhang Xu, 1, &ast Jianwei Wan, 1, &ast Cuihong Wang, 1 Jiatao Liu, 2 Chenqai Qian, 1 Hongyang Tan 3 1 Department of Pharmacy, Shanghai University of Medicine and Health Science Affiliated Zhoupu Hospital, Shanghai, People's Republic of China; 2 Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 3 Clinical Research Center for Mental Disorders, Chinese-German Institute of Mental Health Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hongyang Tan, Clinical Research Center for Mental Disorders, Chinese-German Institute of Mental Health, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, People's Republic of China, Tel +86-18321133996, Email Purpose: Trimethylamine N-oxide (TMAO) is a metabolite of phosphatidylcholine in red meat and other diets, which is associated with cardiovascular and other diseases. The aim of this study is to evaluate the associations of serum TMAO with mild cognitive impairment (MCI) in the Chinese type 2 diabetes mellitus (T2DM) population. Materials and Methods: A total of 253 hospitalized T2DM patients and 150 healthy controls were included in this cross-sectional study. Montreal Cognitive Assessment (MoCA) assessed the cognition function, and the 253 T2DM patients were divided into 74 subjects with MCI and 179 with non-MCI. Demographic data and biochemical test results were evaluated. Serum TMAO level was measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Results: A higher serum TMAO level was observed in T2DM patients compared with the healthy controls (P < 0.001). Among all T2DM patients, the MCI group (n = 74) showed higher serum TMAO levels than the non-MCI group. Spearman correlation test showed that TMAO levels were significantly positively correlated with age (r = 0.147, P = 0.019), body mass index (BMI) (r = 0.153, P = 0.015), diabetes duration (r = 0.160, P = 0.011), HbA1c (r = 0.138, P = 0.029), triglyceride (TG) (r = 0.138, P = 0.029), creatinine (r = 0.184, p = 0.003), hs-CRP (r = 0.243, P < 0.001), and were negatively correlated with HDL-C (r = − 0.144, P = 0.022), BDNF (r = − 0.165, p = 0.009), and MoCA (r = − 0.386, P < 0.001) score (all P < 0.05). Multivariable Logistic regression identified high serum TMAO level as a significant independent factor of MCI in the T2DM patients (OR = 1.404, 95% CI = 1.255– 1.571; P < 0.001). Conclusion: Our study showed that T2DM patients with MCI have elevated serum TMAO levels. Keywords: trimethylamine N-oxide, type 2 diabetes mellitus, mild cognitive impairment, Montreal Cognitive Assessment, healthy control Type 2 diabetes mellitus (DM) is one of the most common severe public health problems in the 21st century globally. 1 China has the highest number of Type 2 diabetes mellitus (T2DM) patients, accounting for over 90% of all diabetes mellitus patients locally. 2 T2DM is amalgamated with a potential risk of dementia, cognitive impairment, and Alzheimer's disease (AD). 3,4 Mild cognitive impairment (MCI) is a transitional state between normal aging and dementia, and subjects have a gradual loss of memory and executive function. Consequently, different morphological changes in the central nervous system (CNS) include decreased hippocampal size and neurogenesis, brain tissue atrophy, and unusual neural electrical property changes. 5–8 These disorders affect tremendous public health care and quality of life. Therefore, there is an urgent need to reveal early diagnostic biomarkers for MCI in T2DM patients. Trimethylamine-N-oxide (TMAO) is a metabolite mainly generated from dietary choline and L-carnitine and its precursor trimethylamine (TMA). Both choline and L-carnitine undergo metabolization by the gut microbiota into TMA, which is further converted into TMAO by liver flavin-containing monooxygenase 3 (FMO3). 9 A major concern in TMAO levels could be the result of dietary differences, suggesting that intestinal microbiota may play a significant role in the variation of TMAO levels. 10 Several studies demonstrated that TMAO could be associated with cardio-renal disorders, including atrial fibrillation, heart failure, chronic kidney disease, and acute myocardial infarction. 11–14 A recent study reported plasma TMAO level as a novel prognostic consequence of cardiovascular diseases (CVD). 15 Previously, a meta-analysis showed a positive d -Abstract Truncated-
endocrinology & metabolism